Ca-Mg Butyrate in Gulf War Illness
Sponsor: VA Office of Research and Development • ClinicalTrials.gov ID: NCT05367245
Recruiting for Similar Conditions?
Sponsors are looking for patients like you. See if you qualify for compensated research studies.
Check Eligibility →Description
The primary objective of this clinical trial is to determine if treatment with Butyrate formulation that consists of butyric acid as calcium and magnesium derivatives (Ca-Mg Butyrate) improves the physical function of men and women Veterans suffering from Gulf War Illness (GWI). The primary outcome measure is a change from baseline on the Short Form Health Survey 36-item (VSF-36), with respect to physical functioning and symptoms. The secondary outcome will focus on the drug's role in (a) restoring gut microbiome and virome, (b) decreasing gastrointestinal disturbances (constipation, diarrhea, pain), (c) decreasing chronic fatigue, (d) decreasing systemic inflammation, and (e) a decrease in cognitive deficits.
Interventions
-
Cal-Mag Butyrate
(Drug)
Supplements
-
Placebo
(Drug)
Only Cal-Mag but no Butyric acid
Eligibility criteria
Conditions
Locations
- VA Long Beach Healthcare System, Long Beach, CA — Long Beach, California, United States
- Miami VA Healthcare System, Miami, FL — Miami, Florida, United States
- VA Salt Lake City Health Care System, Salt Lake City, UT — Salt Lake City, Utah, United States
Partner with Nurenyx
Showcase your study to thousands of motivated patients matching your criteria.
Learn MoreOfficial Source
Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
View Official Record